First Time Loading...

Sutro Biopharma Inc
NASDAQ:STRO

Watchlist Manager
Sutro Biopharma Inc Logo
Sutro Biopharma Inc
NASDAQ:STRO
Watchlist
Price: 3.74 USD 10.16% Market Closed
Updated: May 2, 2024
Section:
 

Wall Street
Price Targets

STRO Price Targets Summary
Sutro Biopharma Inc

Wall Street analysts forecast STRO stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for STRO is 13.15 USD with a low forecast of 8.08 USD and a high forecast of 21 USD.

STRO Lowest Forecast
Wall Street Target
8.08 USD
116% Upside
STRO Average Forecast
Wall Street Target
13.15 USD
252% Upside
STRO Highest Forecast
Wall Street Target
21 USD
461% Upside
Lowest
Price Target
8.08 USD
116% Upside
Average
Price Target
13.15 USD
252% Upside
Highest
Price Target
21 USD
461% Upside

STRO Last Price Targets
Sutro Biopharma Inc

The latest public price target was made on Apr 3, 2024 by Edward Tenthoff from Piper Sandler , who expects STRO stock to rise by 194% over the next 12 months. You can read more about this price target by viewing the article on StreetInsider.

Analyst Price Target Date Article
Edward Tenthoff
Piper Sandler
11 USD
Upside 194%
4 weeks ago
Apr 3, 2024
Sutro Biopharma (STRO) PT Lowered to $11 at Piper Sandler
StreetInsider
Jay Olson
Oppenheimer
10 USD
Upside 167%
4 weeks ago
Apr 3, 2024
Oppenheimer Reiterates Outperform Rating on Sutro Biopharma (STRO)
StreetInsider
Asthika Goonewardene
Truist Financial
18 USD
Upside 381%
1 month ago
Apr 2, 2024
Sutro Biopharma (STRO) PT Lowered to $18 at Truist Securities
StreetInsider
Edward Tenthoff
Piper Sandler
Price Target 11 USD
Upside/Downside 194%
View Source
Jay Olson
Oppenheimer
Price Target 10 USD
Upside/Downside 167%
View Source
Asthika Goonewardene
Truist Financial
Price Target 18 USD
Upside/Downside 381%
View Source
Sutro Biopharma Inc Competitors:
Price Targets
BMRN
Biomarin Pharmaceutical Inc
34% Upside
RCUS
Arcus Biosciences Inc
158% Upside
CYTH
Cyclo Therapeutics Inc
181% Upside
B
002038
Beijing SL Pharmaceutical Co Ltd
396% Upside
BMRN
Biomarin Pharmaceutical Inc
34% Upside
RCUS
Arcus Biosciences Inc
158% Upside
CYTH
Cyclo Therapeutics Inc
181% Upside
B
002038
Beijing SL Pharmaceutical Co Ltd
396% Upside
M
086900
Medy Tox Inc
73% Upside
2INV
2Invest AG
71% Downside
1167
Jacobio Pharmaceuticals Group Co Ltd
280% Upside
MGNX
MacroGenics Inc
63% Upside

Revenue
Forecast

Revenue Estimate
Sutro Biopharma Inc

For the last 6 years the compound annual growth rate for Sutro Biopharma Inc's revenue is 20%. The projected CAGR for the next 3 years is -11%.

20%
Past Growth
-11%
Estimated Growth
Estimates Accuracy
0%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Sutro Biopharma Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-2%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Sutro Biopharma Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-56%
Average Miss
What are analyst estimates?

See Also

Summary
STRO intrinsic value, competitors valuation, and company profile.
DCF Valuation
STRO stock valuation using Discount Cash Flow valuation method.
Relative Valuation
STRO stock valuation using valuation multiples.
Wall Street Estimates
STRO price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
STRO stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is STRO's stock price target?
Price Target
13.15 USD

According to Wall Street analysts, the average 1-year price target for STRO is 13.15 USD with a low forecast of 8.08 USD and a high forecast of 21 USD.

What is Sutro Biopharma Inc's Revenue forecast?
Projected CAGR
-11%

For the last 6 years the compound annual growth rate for Sutro Biopharma Inc's revenue is 20%. The projected CAGR for the next 3 years is -11%.

ALPHA SPREAD
Join more than 133,400+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.